Open Beta
TREN
MetriLume
TREN

US marketsADCT

SEC-sourced researchBeta

ADCT

ADC Therapeutics SA

Company comparison ↗

Data passport

CIK
0001771910
Exchange
NYSE
Business activity
Pharmaceutical Preparations · SIC 2834
Financial inputs
6/6
Filing date
Aug 14, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 70,837,000.0000 USD; December 2025: 81,357,000.0000 USD81.4M USD0 USD0December 2024December 2025
ADCT · Exact amounts and source periods · USD
Period endRevenueFiling date
December 202470,837,000.0000Mar 10, 2026
December 202581,357,000.0000Mar 10, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 202581,357,000.0000-142,623,000.0000-141,174,000.0000323,150,000.0000508,984,000.0000Mar 10, 2026
December 202470,837,000.0000-157,846,000.0000-123,835,000.0000321,980,000.0000524,622,000.0000Mar 10, 2026

Explainable fundamental score

Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.

33/100
Profitability0
Growth65
Balance sheet0
Cash generation0
Data coverage100

Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenues$81.36MJan 1, 2025 – Dec 31, 2025Mar 10, 202610-K
Previous period revenueRevenues$70.84MJan 1, 2024 – Dec 31, 2024Mar 10, 202610-K
Net incomeNetIncomeLoss-$142.62MJan 1, 2025 – Dec 31, 2025Mar 10, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$141.17MJan 1, 2025 – Dec 31, 2025Mar 10, 202610-K
Total assetsAssets$323.15MDec 31, 2025Mar 10, 202610-K
Total liabilitiesLiabilities$508.98MDec 31, 2025Mar 10, 202610-K

New filings

Explore methodology ↗